ChemicalBook > Product Catalog >API >Nervous system drugs >Antidepressants, Antimanics drugs >Moclobemide


Moclobemide Suppliers list
Company Name: Target Molecule Corp
Tel: 781-999-5354 18019718960
Products Intro: Product Name:Moclobemide;Ro111163
Purity:99.95% Package:5 mg;10 mg;25 mg;50 mg;100 mg;200 mg;1 mL * 10 mM (in DMSO) Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: Hangzhou FandaChem Co.,Ltd.
Tel: 008615858145714
Products Intro: Product Name:Moclobemide;Ro111163 fandachem
Purity:As coa Package:As request Remarks:71320-77-9
Company Name: Hubei XinRunde Chemical Co., Ltd.
Tel: +8615102730682; +8618874586545
Products Intro: Product Name:Moclobemide
Purity:99% Package:100g/ bag, 2 kg/ bag, 25kg/ carton or as required Remarks:White to Off-White Solid
Tel: +86 21 5161 9050/ 5187 7795
Products Intro: Product Name:Moclobemide
Purity:98% HPLC Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: career henan chemical co
Tel: +86-0371-55982848
Products Intro: Product Name:Moclobemide
CAS: 71320-77-9
Purity:99% Package:1KG;7USD

Moclobemide manufacturers

  • Moclobemide
  • $10.00 / KG
  • 2021-08-31
  • CAS:71320-77-9
  • Min. Order: 1KG
  • Purity: 99.99%
  • Supply Ability: 200 tons/month
  • Moclobemide USP/EP/BP
  • $1.10 / g
  • 2021-07-27
  • CAS:71320-77-9
  • Min. Order: 1g
  • Purity: 99.9%
  • Supply Ability: 100 Tons min
  • Moclobemide
  • $15.00-10.00 / KG
  • 2021-07-13
  • CAS:71320-77-9
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
Moclobemide Basic information
Product Name:Moclobemide
Synonyms:moclbemide;4-CHLORO-N[2-(4-MORPHOLINYL)ETHYL]-BENZAMIDE (MOCLOBEMIDE);Ro-11-1163, Aurorix, Manerix, Moclamine, p-Chloro-N-(2-morpholinoethyl)benzamide;MODOBEMDE;p-Chlor-N-(2-morpholinoethyl)benzamid;4-Chloro-(2-(4-morpholinyl)ethyl)benzamide;Moclobemide (base and/or unspecified salts);4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide, Aurorix, Moclamine
Product Categories:API's;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs;Active Pharmaceutical Ingredients;Monoamine Oxidase
Mol File:71320-77-9.mol
Moclobemide Structure
Moclobemide Chemical Properties
Melting point 137°C
Boiling point 447.7±40.0 °C(Predicted)
density 1.206±0.06 g/cm3(Predicted)
storage temp. room temp
solubility DMSO: >20mg/mL
form solid
color white
Merck 14,6226
CAS DataBase Reference71320-77-9(CAS DataBase Reference)
NIST Chemistry ReferenceMoclobemide(71320-77-9)
Safety Information
Hazard Codes Xn,T+
Risk Statements 22-37/38-41-26/27/28
Safety Statements 26-39-45-36/37/39-22
WGK Germany 2
RTECS CV2462000
HazardClass 6.1(b)
PackingGroup III
HS Code 29349990
Hazardous Substances Data71320-77-9(Hazardous Substances Data)
ToxicityLD50 in rats (mg/kg): 707 orally (Burkard, Wyss)
MSDS Information
Aurorix English
Moclobemide Usage And Synthesis
DescriptionMoclobemide is the first of a new generation of non-hydrazine, reversible MAO-A inhibitors useful in the treatment of depression. Moclobemide is a selective inhibitor of MAO-A, allowing tyramine to be metabolized by MAO-B. In controlled studies, moclobemide was clinically superior to desipramine and showed no cholinergic or cardiovascular side-effects. A metabolite is currently under investigation for treatment of Parkinson’s disease,.
DescriptionMoclobemide (Item No. 24361) is an analytical reference standard categorized as an antidepressant. This product is intended for research and forensic applications.
Chemical PropertiesWhite to Off-White Solid
OriginatorHoffmann-LaRoche (Switzerland)
UsesA reversible monoamine oxidase inhibitor
UsesAntidepressant;Mono amine oxidase inhibitor (Type A)
UsesA reversible monoamine oxidase inhibitor.
DefinitionChEBI: A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Brand nameAurorix
Mechanism of actionMoclobemide is an RIMA that preferentially inhibits MAO-A (~80%) and, to a lesser extent, MAO-B (20–30% inhibition), thereby increasing the concentration of 5-HT, NE, and other catecholamines in the synaptic cleft and in storage sites. During chronic therapy with the MAOIs, adaptive changes at the noradrenergic and serotonergic receptors occur (“downregulation”) as a result of neurotransmitter hypersensitivity because of prolonged concentrations of NE and 5-HT at the postsynaptic receptor. This mechanism is likely the basis for its antidepressant activity. Inhibition of MAO-A by moclobemide is short-acting (maximum, 24 hours) and reversible. This is in contrast to phenelzine, which is nonselective, long-acting, and irreversible in its binding to MAO-A and MAO-B.
The pharmacokinetics for moclobemide are linear only up to 200 mg; at higher doses, nonlinear pharmacokinetics are observed. Although well absorbed from the GI tract, the presence of food reduces the rate but not the extent of absorption of moclobemide. Small quantities of moclobemide are distributed into human breast milk. Moclobemide undergoes a complex metabolism, initially involving morpholine carbon and nitrogen oxidation, deamination, and aromatic hydroxylation. The N-oxide and ring-opened metabolites retain some in vitro MAO-A inhibition. Moclobemide is a weak inhibitor of CYP2D6 in vitro. It is extensively metabolized in the liver by oxidation and is eliminated primarily into the urine as conjugates. Less than 1% of an administered dose of moclobemide is eliminated unmetabolized.
Because moclobemide is partially metabolized by the polymorphic isozymes CYP2C19 and CYP2D6, plasma concentrations of moclobenmide may be affected in patients who are poor metabolizers. In patients who are slow metabolizers, the AUC for moclobemide was 1.5 times greater than the AUC in patients who are extensive metabolizers and receiving the same dose. This increase is within the normal range of variation (up to twofold) typically seen in patients.
Drug interactionsDrug interactions for the RIMAs include interaction with SSRI antidepressants, which can cause the 5-HT syndrome. The effect of stimulant drugs, such as methylphenidate and dextroamphetamine (used to treat ADHD), may be increased. Some over-the-counter cold and hay fever decongestants (i.e., sympathomimetic amines) can have increased stimulant effects. Selegiline, a selective MAO-B used for Parkinson's disease, should not be used concurrently with the RIMAs. Unlike the irreversible MAOIs, no significant interactions with foods occur, because the selective inhibition of MAO-A does not stop the metabolism of tyramine. The RIMAs must not be taken concurrently with a nonreversible MAOI.
Tag:Moclobemide(71320-77-9) Related Product Information
Olanzapine ISOCARBOXAZID (200 MG) Minoxidil Entacapone Penfluridol Citalopram Trazodone Paroxetine Paroxetine hydrochloride Benzamide CHLOANTRANILIPROLE Difluorochloromethane AURORA 16306 (2,4-DICHLOROPHENYL)-N-(2-MORPHOLIN-4-YLETHYL)FORMAMIDE Moclobemide 4-t-Butylbenzamide p-Aminobenzamide